Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism.

[1]  E. Lesaffre,et al.  Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. , 1992, Journal of the American College of Cardiology.

[2]  K. Peterson,et al.  Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography. , 1992, Radiology.

[3]  F. Van de Werf,et al.  Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction. , 1991, The American journal of cardiology.

[4]  D. Collen,et al.  Thrombolysis with Bolus Injections and Infusions of Tissue-type Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis , 1991 .

[5]  J. Hirsh,et al.  A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. , 1990, Chest.

[6]  A. Maseri,et al.  Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.

[7]  G. Agnelli.  Rationale for bolus t-PA therapy to improve efficacy and safety. , 1990, Chest.

[8]  J. Ducas,et al.  Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics. , 1989, Circulation.

[9]  P. Holvoet,et al.  Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. , 1989, Circulation.

[10]  J. Henkin,et al.  UROKINASE VERSUS TISSUE PLASMINOGEN ACTIVATOR IN PULMONARY EMBOLISM , 1988, The Lancet.

[11]  E. Braunwald,et al.  RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM , 1988, The Lancet.

[12]  E. Israels,et al.  Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes. , 1988, Circulation.

[13]  P. Mombaerts,et al.  Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. , 1988, Circulation.

[14]  J. Loscalzo,et al.  Thrombolytic therapy of acute pulmonary embolism: current status and future potential. , 1987, Journal of the American College of Cardiology.

[15]  J. Hirsh,et al.  The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. , 1985, Thrombosis research.

[16]  P. Petitpretz,et al.  Effects of a single bolus of urokinase in patients with life-threatening pulmonary emboli: a descriptive trial. , 1984, Circulation.

[17]  K. Kurppa,et al.  Letter: Timolol, hydrochlorothiazide, blood-pressure, and renin in essential hypertension. , 1976, Lancet.

[18]  G. Sutton,et al.  Comparison of Streptokinase and Heparin in Treatment of Isolated Acute Massive Pulmonary Embolism* , 1971, British heart journal.

[19]  Benraad Ah,et al.  POTASSIUM CHLORIDE AND INTESTINAL ULCERATION. , 1965 .

[20]  S. Wessler,et al.  The treatment of venous thrombosis and pulmonary embolism. , 1962, The Medical clinics of North America.